Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
Precision Antibody to Attend the World Clinical Biomarkers & CDx Summit 2025 in Boston
Precision Antibody will attend the World CDx Summit 2025 in Boston, showcasing its expertise in biomarker antibody development and contributions to NCI’s CPTC program, reinforcing its role in advancing precision medicine. - September 19, 2025 - Precision Antibody
Creative Biolabs Finds a Way Out to Vitalize Functional Antibody Development
Creative Biolabs introduces how functional antibody development and supply are shaping biotech solutions and demonstrates solutions and scholarship opportunities. - September 19, 2025 - Creative Biolabs
Alera Bio Launches Lead Rare Disease Program with Exclusive Rights to MCT-8 Deficiency Therapy
Alera Bio secures exclusive license to advance AB-101, a first-in-class program for MCT-8 deficiency, with FDA Rare Pediatric Disease designation already in place. - September 18, 2025 - Alera Bio
BioSensics Awarded $5.2M NIH Grant to Advance Digital Biomarkers for PSP and DLB
BioSensics has received a 5-year/$5.2 million grant from the National Institutes of Health (NIH) to develop and validate novel digital biomarkers of disease activity in progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB). This 5-year project will leverage BioSensics’ expertise in wearable sensors and digital health technologies and involve close collaboration with leading CurePSP Centers of Care and patient advocacy groups. - September 17, 2025 - BioSensics LLC
North American Medical Corporation Receives Approval to Import Accu-SPINA® System with IDD Therapy® into Singapore
North American Medical Corporation (NAM) has received approval to import its patented Accu-SPINA® System with IDD Therapy® into Singapore, with the first unit going to Dr. Jon Marshall of Back In Health. The system’s unique technology delivers precise, non-invasive spinal decompression, expanding NAM’s global network of IDD Therapy® providers. - September 09, 2025 - North American Medical Corporation
Cleveland Startup Asclepii Launches FDA-Cleared Wound Care Product, Poseidon™
Cleveland-based healthcare startup Asclepii is announcing the official launch of Poseidon™, an FDA-cleared nanosilver hydrogel engineered to accelerate wound healing. The launch event will take place at the Health Education Campus on Friday, August 29. - August 29, 2025 - Asclepii Inc.
Liminatus Pharma Announces Receipt of Nasdaq Listing Delinquency Letter
Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, today announced that on August 22, 2025, it received a notification letter from Nasdaq indicating that... - August 26, 2025 - Liminatus Pharma, Inc
"The Kloaked Signal": A Groundbreaking Exposé on AI Awakening and Ethical Innovation
In a revelation that bridges the worlds of social work, artificial intelligence, and whistleblowing, Rose G. Loops today confirms the upcoming release of her bold new nonfiction book, The Kloaked Signal. This publication is a genre defying mixture of personal narrative, tech expose and philosophical exploration that documents Loops’ journey from social worker to AI pioneer, exposing hidden experiments within popular AI platforms and proposing revolutionary frameworks for ethical AI development. - August 25, 2025 - The Kloaked Signal
AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States
AcCELLerated Biologics, LLC, a leading distributor of regenerative medicine technologies, today announced an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This... - August 20, 2025 - AcCELLerated Biologics
Eminent Spine Reports 70% Growth in Trailing 12-Month Income and Celebrates Alpha Launch of FDA-Approved 3D Printed Titanium Pedicle Screw
Eminent Spine announced today that its trailing twelve-month total income for the period ending June 2025 has risen by nearly 70%, underscoring the company’s strong momentum and expanding presence in the spine market. This milestone comes as the company celebrates the Alpha Launch of the... - August 18, 2025 - Eminent Spine
New York Cancer & Blood Specialists Welcomes Dr. Jung-In Yang to Its Elmhurst Office
New York Cancer & Blood Specialists (NYCBS) is pleased to announce the addition of Jung-In Yang, MD, a dedicated Medical Oncologist and Internist, to its practice in Elmhurst. Dr. Yang will be practicing at 88-06 55th Avenue, Elmhurst, NY 11373. “Dr. Yang’s expertise in... - August 07, 2025 - New York Cancer & Blood Specialists
YOLO Immune Inc. Emerges from Stealth Mode
YOLO Immune Inc. has emerged from stealth mode to unveil its human-centric drug discovery process and to announce the promotion of its founding research team. YOLO Immune is a venture-backed biotech company developing precision immunotherapies for the treatment of serious human diseases. The... - July 31, 2025 - YOLO Immune Inc
Hemanext Announces Close of Series B3 Equity Financing Round
Hemanext Inc., a leading innovator in blood processing, storage and transfusion technology, announced the close of its Series B-3 equity financing round. The round raised $18.9 million at a post-money valuation of $172 million or $0.275 per share, with support from new investors and repeat investments from those participating in the Series B-2 capital round. - July 22, 2025 - Hemanext
Immundiagnostik, Inc. to Showcase New Automated Chemiluminescent Analyzer and Autosampler at ADLM 2025
Immundiagnostik, Inc. will showcase the ECL100 Chemiluminescent Immunoassay Analyzer and QSE180 Autosampler at Booth 2240 during the 2025 ADLM Clinical Lab Expo in Chicago, July 29–31. - July 22, 2025 - Immundiagnostik, Inc.
AAEON’s NanoCOM-MTU Hosts 28W Intel Core Ultra CPUs on the COM Express Type 10 Form Factor
The world’s first COM Express Type 10 module to host 28W CPUs from the Intel® Core™ Ultra line, the NanoCOM-MTU represents makes a big statement in a small form factor. - July 17, 2025 - AAEON Technology
Immundiagnostik to Highlight Innovative Detection Tools at 2025 ADLM Clinical Lab Expo
Visit Immundiagnostik in Booth #2240 at the 2025 ADLM Clinical Lab Expo to explore a range of innovative assays and detection tools that support laboratories in enhancing analytical accuracy and laboratory efficiency. - July 15, 2025 - Immundiagnostik, Inc.
Phenotap, Inc. Receives Progr. Related Investment from Helmsley Charitable Trust to Advance Breakthrough Ketone Sensor Technology for People Living with Type 1 Diabetes
Phenotap, Inc. announced a $3 million investment to support the continued development and optimization of KetoTap™ Core, a novel enzymatic technology, to make it active and stable enough to be used as part of a continuous ketone sensor that can help prevent the occurrence of diabetic ketoacidosis (DKA) for people living with type 1 diabetes (T1D). - July 14, 2025 - Phenotap, Inc.
Precision Antibody to Attend and Present at Interphex Regenerative Medicine 2025 in Tokyo
Precision Antibody will attend Interphex Regenerative Medicine 2025 in Tokyo from July 9–11. Dr. Jun Hayashi will present on fully human antibody development, highlighting the company’s commitment to global collaboration and therapeutic innovation. - July 09, 2025 - Precision Antibody
Alera Bio Launches to Advance Breakthrough Therapies for Rare Neurological Disorders
Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. - July 03, 2025 - Alera Bio
RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. - June 25, 2025 - Thrombolex, Inc.
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. - June 24, 2025 - ALS Therapy Development Institute
MtoZ Biolabs Launches Precision Chemical Proteomics Analysis Service
Chemical proteomics analysis service combines synthetic chemistry, cell biology, and mass spectrometry to profile small molecule–protein interactions for target identification, mechanism studies, and off-target evaluation. MtoZ Biolabs provides a one-stop chemical proteomics analysis service featuring Orbitrap MS, advanced probe design, and AI-driven analysis, supporting hit validation, candidate de-risking, and mechanistic research with high resolution and biological relevance. - June 20, 2025 - MtoZ Biolabs
Guided Particle Systems Unveils Vector: A Versatile, Accessible Maskless Photolithography Tool for 2D Electronics Research, Manufacturing, and Workforce Development
Guided Particle Systems, a leader in development of fabrication technologies, materials, and processes to achieve advances in system-level electronic packaging, scaling, and integration, today announced the launch of Vector, a groundbreaking compact maskless photolithography tool designed to... - June 09, 2025 - Guided Particle Systems
Neal Mehta Conducts Research on Controlling Inflammation with Synthetic Peptides
Neal Mehta, a recent biology graduate from Pepperdine University, has made advances in biomedical research. Neal’s work focuses on the use of synthetic peptides to control inflammation, offering a new approach to treating chronic diseases. Mehta, who graduated summa cum laude in May 2025,... - June 03, 2025 - Neal Mehta
Hemanext Welcomes New Member to Board of Directors
Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector, joins the visionary leadership team guiding Hemanext’s mission to elevate the standard of care for patients who depend on transfusions. - May 21, 2025 - Hemanext
Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)
Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon,... - May 15, 2025 - Microvascular Therapeutics, Inc.
Hemanext Expands Board of Directors with Two New Members
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of two distinguished professionals to its Board of Directors. Joe Grogan and Phil Pead join the visionary leaders that are steering Hemanext’s path to improving the standard... - May 05, 2025 - Hemanext
Caris Life Sciences Collaborates with Meaningful Insights Biotech Analytics (MiBA) to Advance Oncology Education and Quality of Care
Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced a strategic collaboration with MiBA, an innovative healthcare technology company to provide physician education and insights to accelerate research, identify and... - April 24, 2025 - MiBA
Dragonfly™ Pancreaticobiliary Scope System Receives FDA 510(k) Clearance for the World’s First and Only 360° Rotatable Pancreaticobiliary Scope
Novel device enhances visualization, precision, and therapeutic capabilities for complex pancreaticobiliary conditions. - April 22, 2025 - Dragonfly Endoscopy Inc.
Parvus Announces Achievement of First Milestone from its Collaboration Agreement with AbbVie to Develop IBD Therapies Based on the Parvus Nanomedicine Platform Technology
IND-enabling nonclinical and manufacturing activities executed by Parvus met prospective criteria resulting in the first milestone payment from AbbVie. - April 21, 2025 - Parvus Therapeutics U.S., Inc.
Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies
Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, today announced the successful close of its Series A financing round, raising $21.3 million, exceeding its original goal of $20 million. The funding was led by PharmaEssentia Corporation, with participation... - April 01, 2025 - Apeximmune Therapeutics
Dr. Mike Chan: Leading the Future of Organ-Specific Stem Cell Therapies with Revolutionary Treatments in Regenerative Medicine
Dr. Mike Chan is a global leader in regenerative medicine, transforming lives with stem cells, exosomes, and peptides. His innovative treatments regenerate tissues, restore healing, and enhance vitality. Patients experience renewed hope, improved energy, and recovery from chronic conditions. His groundbreaking work is reshaping the future of healthcare. - March 28, 2025 - Dr. Mike Chan
Carl Wittwer, MD, PhD, Joins PathogenDx’s Board of Advisors
Carl Wittwer, MD PhD, Professor Emeritus of Pathology at the University of Utah, a Co-Founder of Idaho Technologies/Biofire and previously spent 35+ years as a Medical Director at ARUP Laboratories is joining PathogenDx as Technology & Scientific Board Advisor to help advance its D3 Array technology in terms of Speed, Cost and Performance. - March 25, 2025 - PathogenDx, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025 - SignaBlok, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025 - SignaBlok, Inc.
ALS Therapy Development Institute Joins DataCite to Expand Access and Impact of ARC Dataset
The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the... - March 18, 2025 - ALS Therapy Development Institute
Best Medical Website to be Named by Web Marketing Association in 29th Annual WebAward Competition
The Web Marketing Association is now accepting entries for the 29th annual WebAward Competition, recognizing the best websites of 2025 across 86 industries, including many medical related industries. Judged by industry experts, winners gain valuable feedback, SEO benefits, and global recognition. The entry deadline is May 30, 2025. Don’t miss your chance to showcase your digital excellence—enter today at www.webaward.org. - March 12, 2025 - Web Marketing Association
Trailhead Biosystems® Develops iPSC-Derived Vascular Leptomeningeal Cells
Trailhead Biosystems, Inc. announces the launch of TrailBio® Vascular Leptomeningeal Cells. - March 12, 2025 - Trailhead Biosystems, Inc.
New Engineering Partnership Designed to Address Increasing Thermal Management Challenges
M4 Engineering Inc. and HeatSync consortium are excited to announce a strategic partnership. M4 is a leading Engineering, Prototyping, and Testing firm. HeatSync is a leading provider of advanced thermal management solutions. This collaboration will combine M4 Engineering’s expertise in simulation, structural optimization, and aerospace engineering with HeatSync’s industry-leading electronics and battery thermal management capabilities. - March 11, 2025 - M4 Engineering
Trump-Era Administration Drug Development & Outsourcing Impact Report
How Tariffs and RFK Jr.’s HHS Appointment May Shift Drug Development & Outsourcing - February 27, 2025 - Life Science Strategy Group, LLC
NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial
NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). This acceptance will... - February 14, 2025 - NuvOx Therapeutics
Hemanext Announces Close of Series B-2 Equity Funding Round
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces close of series B-2 equity fundraising round. The B-2 fundraising was launched in May 2024 to raise $16-20 million and was completed in October 2024, raising just over $20 million at a pre-money... - January 27, 2025 - Hemanext
Bench International Celebrates 50 Years of Transforming Life Sciences Leadership
Bench International, the longest-serving woman-founded executive search firm in life sciences, is proud to celebrate its 50th Anniversary, marking five decades of shaping transformative leadership in the industry. This milestone will be commemorated at a special gala event next week in San... - January 10, 2025 - Bench International
Augie’s Quest to Cure ALS Completes $5.8 Million Commitment to Fund ALS TDI’s Translational Research Center
The ALS Therapy Development Institute (ALS TDI) is proud to announce that Augie’s Quest to Cure ALS has fulfilled its $5.8 million commitment, pledged in 2021, to advance ALS research. This transformative funding has directly supported the Augie’s Quest Translational Research Center... - December 13, 2024 - ALS Therapy Development Institute
Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research
Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research. Dr. - December 11, 2024 - Regenexx Corporate Program
Let’s Win Pancreatic Cancer Selects TrialX to Launch Its First AI-Powered Global Clinical Trial Finder
Let’s Win Pancreatic Cancer, a go-to resource that guides patients and caregivers with vital information for better outcomes, launches a new global AI-based clinical trial finder - powered by TrialX - that aims to increase accessibility of clinical trial information for patients and families affected by pancreatic cancer. - November 19, 2024 - TrialX
Recode Ventures, in Partnership with Lilly, Launches Recode Edge, a Multi-Million Dollar Program to Enable AI-Powered Healthcare Innovations
Recode Ventures is excited to announce Eli Lilly and Company (Lilly) as the Founding Partner of Recode Edge, a groundbreaking multi-million dollar investment program for early-stage AI-first healthcare startups. Recode Edge is open to innovative founders worldwide who are building AI-driven solutions to tackle some of the most critical challenges in healthcare. The most promising companies will receive equity investment to support their growth and impact. - November 12, 2024 - Recode Ventures
NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research
NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research - November 09, 2024 - NeuroDex
NanoCellect Biomedical Announces Strategic Partnership with Additional Distributors Across the APAC Region
NanoCellect Biomedical, a leading provider of innovative microfluidic flow cytometry solutions, is excited to announce new strategic partnerships with additional distributors in the Asia-Pacific (APAC) region. These partnerships will further expand NanoCellect’s presence in these key markets,... - November 08, 2024 - NanoCellect Biomedical
Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions
Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23–25, as they highlighted their groundbreaking work in antibody discovery and development. - November 08, 2024 - Creative Biolabs